JP2018509887A5 - - Google Patents

Download PDF

Info

Publication number
JP2018509887A5
JP2018509887A5 JP2017539548A JP2017539548A JP2018509887A5 JP 2018509887 A5 JP2018509887 A5 JP 2018509887A5 JP 2017539548 A JP2017539548 A JP 2017539548A JP 2017539548 A JP2017539548 A JP 2017539548A JP 2018509887 A5 JP2018509887 A5 JP 2018509887A5
Authority
JP
Japan
Prior art keywords
hngal
hngal mutein
ang
mutein
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017539548A
Other languages
English (en)
Japanese (ja)
Other versions
JP6839087B2 (ja
JP2018509887A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/051657 external-priority patent/WO2016120307A1/en
Publication of JP2018509887A publication Critical patent/JP2018509887A/ja
Publication of JP2018509887A5 publication Critical patent/JP2018509887A5/ja
Application granted granted Critical
Publication of JP6839087B2 publication Critical patent/JP6839087B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017539548A 2015-01-28 2016-01-27 血管新生に特異的な新規のタンパク質 Expired - Fee Related JP6839087B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15152826 2015-01-28
EP15152826.2 2015-01-28
PCT/EP2016/051657 WO2016120307A1 (en) 2015-01-28 2016-01-27 Novel proteins specific for angiogenesis

Publications (3)

Publication Number Publication Date
JP2018509887A JP2018509887A (ja) 2018-04-12
JP2018509887A5 true JP2018509887A5 (enExample) 2019-03-07
JP6839087B2 JP6839087B2 (ja) 2021-03-03

Family

ID=52396588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017539548A Expired - Fee Related JP6839087B2 (ja) 2015-01-28 2016-01-27 血管新生に特異的な新規のタンパク質

Country Status (14)

Country Link
US (2) US10526382B2 (enExample)
EP (1) EP3250586B1 (enExample)
JP (1) JP6839087B2 (enExample)
KR (1) KR20170105609A (enExample)
CN (1) CN107207574A (enExample)
AU (1) AU2016212087B2 (enExample)
BR (1) BR112017015773A2 (enExample)
CA (1) CA2973640A1 (enExample)
DK (1) DK3250586T3 (enExample)
MX (1) MX384075B (enExample)
RU (1) RU2720688C2 (enExample)
SG (2) SG11201705278QA (enExample)
WO (1) WO2016120307A1 (enExample)
ZA (1) ZA201704320B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
EP3145945B1 (en) 2014-05-22 2020-07-15 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
SG11201705278QA (en) 2015-01-28 2017-07-28 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
PH12017501583B1 (en) 2015-05-04 2023-01-20 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
DK3298030T5 (en) 2015-05-18 2024-10-07 Pieris Pharmaceuticals Gmbh Anti-cancerfusionspolypeptid
EP3298029A1 (en) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
US10703810B2 (en) 2015-11-30 2020-07-07 Pieris Australia Pty Ltd. Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
JP2022515256A (ja) 2018-12-25 2022-02-17 ソル - ゲル テクノロジーズ リミテッド Egfr阻害剤を含む組成物による皮膚障害の治療
CN113939307A (zh) 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3177098A1 (en) 2020-06-05 2021-12-09 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb
EP4215204A1 (en) * 2022-01-24 2023-07-26 Universitat Pompeu Fabra Human neutrophil gelatinase-associated lipocalin derived from recombinant bacteria and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
AU696387B2 (en) 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
JP3839667B2 (ja) 1998-06-08 2006-11-01 エフ.ホフマン−ラ ロシュ アーゲー 慢性C型肝炎の処置のためのPeg−INF−アルファ及びリバビリンの使用
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2225268B1 (en) 2007-10-19 2012-08-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
EP2245054B1 (en) * 2008-01-30 2018-11-28 Pieris Pharmaceuticals GmbH Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same
US8420051B2 (en) * 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
CA2817779C (en) * 2010-11-15 2019-02-19 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
EP2920202B1 (en) * 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
GB201223053D0 (en) * 2012-12-20 2013-02-06 Medical Res Council Receptor
SG11201705278QA (en) 2015-01-28 2017-07-28 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
EP3259282A1 (en) 2015-02-18 2017-12-27 Sanofi Novel proteins specific for pyoverdine and pyochelin
PH12017501583B1 (en) 2015-05-04 2023-01-20 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
EP3298029A1 (en) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Similar Documents

Publication Publication Date Title
JP6779252B2 (ja) IL−1βへの結合メンバー
CN112646031B (zh) 抗4-1bb纳米抗体及其用途
RU2017128105A (ru) Новые белки, специфические в отношении ангиогенеза
KR102408356B1 (ko) 항―axl 항체
KR102453226B1 (ko) 항―axl 항체
US20230340158A1 (en) Anti-vegf-anti-pd-l1 bispecific antibody, pharmaceutical composition of same, and uses thereof
JP2019506140A5 (enExample)
AU2016347495A1 (en) New polypeptide having affinity to PD-L1
KR101739489B1 (ko) 인간 유래 항-인간 표피 생장인자 수용체 항체 및 그의 코딩 유전자와 용도
KR101541478B1 (ko) 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
JP2018532372A5 (enExample)
KR20140130685A (ko) Cx3cr1-결합 폴리펩타이드
JP7743406B2 (ja) 抗bcma car抗体、コンジュゲートおよび使用方法
JP2005528914A5 (enExample)
JP2019505565A5 (enExample)
JP2023537958A (ja) Bcmaと結合する単一可変ドメイン及び抗原結合分子
KR20240023095A (ko) Vegf 및 ang2에 결합하는 이중특이적 결합 분자 및 이의 사용
CA3114295A1 (en) Il-36 antibodies and uses thereof
CA3208368A1 (en) Vegfa-binding molecules
WO2010065496A1 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
WO2023221935A1 (zh) 结合pd-l1和cldn18.2的抗体及其用途
WO2016112497A1 (zh) 人源抗人α干扰素抗体及其应用
WO2016059068A1 (en) Vegfr-2 binding polypeptides
WO2016059057A1 (en) Vegfr-2 binding polypeptides
EP4482861A2 (en) Fully human monoclonal antibodies against human progranulin